

Published in final edited form as:

J Neurosci. 2011 April 20; 31(16): 5909–5920. doi:10.1523/JNEUROSCI.6787-10.2011.

Interplay of Chemical Neurotransmitters Regulates Developmental Increase in Electrical Synapses

Won-Mee Park^{1,3}, Yongfu Wang^{1,3}, Soodong Park², Janna V. Denisova¹, Joseph D. Fontes², and Andrei B. Belousov¹

¹ Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA

² Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA

Abstract

Coupling of neurons by electrical synapses (gap junctions) transiently increases in the mammalian CNS during development. We report here that the developmental increase in neuronal gap junction coupling and expression of connexin 36 (Cx36; neuronal gap junction protein) are regulated by an interplay between the activity of group II metabotropic glutamate receptors (mGluR) and GABA_A receptors. Specifically, using dye coupling, electrotonic coupling, western blots and siRNA in the rat and mouse hypothalamus and cortex *in vivo* and *in vitro*, we demonstrate that activation of group II mGluRs augments, and inactivation prevents, the developmental increase in neuronal gap junction coupling and Cx36 expression. However, changes in GABA_A receptor activity have the opposite effects. The regulation by group II mGluRs is via cAMP/PKA-dependent signaling and by GABA_A receptors is via Ca²⁺/PKC-dependent signaling. Further, the receptor-mediated up-regulation of Cx36 requires a neuron-restrictive silencer element in the Cx36 gene promoter and the down-regulation involves the 3'UTR of the Cx36 mRNA, as shown using RT-qPCR and luciferase reporter activity analysis. In addition, the MTT analysis indicates that mechanisms for the developmental increase in neuronal gap junction coupling directly control the death/survival mechanisms in developing neurons. Altogether, the results suggest a multi-tiered strategy for chemical synapses in developmental regulation of electrical synapses.

Keywords

gap junctions; connexin 36; metabotropic glutamate receptors; GABA_A receptors; neuronal death; electrical synapses; development

Introduction

Transient coupling of large groups of neurons by electrical synapses (gap junctions) is a general phenomenon in the developing mammalian CNS: it has been documented in different regions of the CNS (neocortex, hippocampus, hypothalamus, striatum, locus coeruleus, spinal cord, etc.) and in different species (rat, mouse, ferret, opossum, etc.) (Bennett and Zukin, 2004). Neuronal gap junction coupling increases during embryonic and/or early postnatal development and plays an important role in a number of developmental events, including neuronal differentiation, cell death, cell migration, synaptogenesis and

Correspondence should be addressed to: Andrei Belousov, Department of Molecular and Integrative Physiology, University of Kansas Medical Center, 2146 W. 39th Avenue, Kansas City KS 66160, abelousov@kumc.edu.

³These authors contributed equally to this work.

neural circuit formation (Allen and Warner, 1991; Walton and Navarrete, 1991; Peinado et al., 1993; Lin et al., 1998; Bani-Yaghoob et al., 1999; Personius et al., 2001; de Rivero Vaccari et al., 2007). It is believed that the contributions of gap junctions are via the passage of Ca^{2+} , IP_3 , cAMP and small molecules between the cells and coordination of metabolic and transcriptional activities in developing neurons (Kandler and Katz, 1998). In addition, gap junctions contribute to the generation of the highly synchronized excitatory electrical activity that is a hallmark of the developing brain (Feller et al., 1996; Ben-Ari, 2001). During later stages of development, neuronal gap junction coupling decreases (Arumugam et al., 2005). However, it increases in the mature CNS during neuronal injuries, such as ischemia, traumatic brain injury, inflammation and epilepsy (Chang et al., 2000; Frantseva et al., 2002; de Pina-Benabou et al., 2005; Nemani and Binder, 2005; Thalakoti et al., 2007).

The developmental uncoupling of neuronal gap junctions occurs in response to increasing chemical synaptic (glutamatergic) transmission and activation of *N*-methyl-D-aspartate (NMDA) receptors (Arumugam et al., 2005). In addition, acute modulation of neuronal gap junction coupling by a number of neurotransmitter receptors in the developing and mature CNS has been reported (Hatton, 1998). However, whether chemical neurotransmitter receptors also regulate the increases in neuronal gap junction coupling that occur during development and injuries is not known.

Here we studied the cellular and molecular mechanisms for the developmental increase in neuronal gap junction coupling. The model system for the present study is the hypothalamus, which expresses gap junctions and is critical for homeostatic regulation and coordination of cardiovascular, nervous, and endocrine functions (Saper, 2004). We demonstrate that the developmental increase in neuronal gap junction coupling and expression of connexin 36 (Cx36; neuronal gap junction protein) are regulated by an interplay between the activity of group II metabotropic glutamate receptors (mGluR) and GABA_A receptors (GABA_ARs). We also show that this regulation is via the neuron-restrictive silencer element (NRSE) in the Cx36 gene promoter and post-transcriptional control of Cx36 mRNA. Finally, our data suggest that the mechanisms for the developmental increase in neuronal gap junction coupling contribute to the regulation of neuronal death/survival mechanisms in developing neurons.

Materials and Methods

Animal care

The use of animal subjects in these experiments was approved by the University of Kansas Medical Center Animal Care and Use Committee. The experiments were conducted in accordance with NIH guidelines. Sprague-Dawley rats, Cx36 knockout mice (C57bl/6 background strain) and wild-type mice (C57bl/6) of either sex were used. The Cx36 knockout was originally created by Dr. David Paul (Harvard Medical School). Mice were genotyped as described (de Rivero Vaccari et al., 2007).

Pharmacological treatments of animals

Rat pups of either sex received daily subcutaneous injections of drugs in 3 increasing sets of concentrations: LY379268 - 3, 5, and 7 mg/kg; LY341495 - 1.5, 2, and 2.5 mg/kg; muscimol - 0.25, 0.5, and 0.75 mg/kg; bicuculline - 1, 1.25, and 1.5 mg/kg; administered, respectively, on postnatal days 1–5 (P1-5; dissolved in 20 μl of sterile saline), P6-10 (40 μl), and P11-15 (60 μl). Control animals received the corresponding volumes of sterile saline. The forebrain was dissected and weighted on P15 and only animals that received muscimol administrations demonstrated slightly reduced forebrain weight (not shown). However, because the loading of protein in all western blots was normalized (i.e., 50 μg of protein per

lane) and the expression of tubulin and glycer-aldehyde-3-phosphate dehydrogenase (GAPDH) in the hypothalamus was not different between the control and muscimol-treated animals (not shown), we concluded that a decrease in Cx36 expression in muscimol-treated rats was rather specific, i.e., it reflected the GABA_AR-dependent down-regulation of Cx36 and was not due to a non-specific decrease in the amount of protein (e.g., because of decrease in the size of the forebrain).

Brain slice and culture preparations and culture treatments

To prepare brain slices, rats were anesthetized (nembutal; 70 mg/kg; intraperitoneal injection, i.p.), sacrificed, the brain was removed, and 400 μ m-thick coronal hypothalamic slices were prepared (at 2–4°C) and kept (at 20–22°C) in artificial cerebrospinal fluid as described (Belousov and van den Pol, 1997). Cultures were prepared as reported previously (Belousov et al., 2001) from the medial hypothalamus or somatosensory cortex obtained from day 18–19 (rat) or 16–17 (mouse) embryos. Pregnant animals were anesthetized (nembutal; 70 mg/kg; i.p.) before embryos were removed. After disaggregation using papain, neurons were plated on glass coverslips and raised in Neurobasal medium (Invitrogen, Carlsbad, CA, USA, cat.# 21103), in which the percentage of neurons reaches ~95% (Wang et al., 2008). The medium was supplemented with B-27 (Invitrogen, cat.# 17504) and 0.5 mM L-glutamine. The culture medium was changed twice a week. Drug and small interfering RNA (siRNA) treatments and luciferase construct transfections were performed using sister cultures. Cell survival was estimated by analyzing the number of live neurons as described (Belousov et al., 2001) and none of the chronic treatments reduced neuronal survival as compared to the control (only luciferase construct transfections and siRNA treatments induced neurodegeneration in cultures after, respectively, 5 and 7 days; therefore, in those experiments cells were exposed to the agents for not more than 4 and 6 days, respectively). Dendritic processes were analyzed using calcein AM staining and were only affected by activation of GABA_ARs (slight increase) and inactivation of GABA_ARs (slight decrease). However, because these changes were opposite to those in Cx36 expression and dye coupling, we concluded that the changes in dendrites were not responsible for alterations in the expression of gap junctions. For chronic GABA_AR blockade *in vitro*, we followed a previously proposed protocol (Muller et al., 1993), where for maximal effect the use of both bicuculline and picrotoxin was proposed.

Dye coupling

Dye coupling in slices and cultures was performed as described in detail (Arumugam et al., 2005). Briefly, the pipette solution contained (mM): 145 KMeSO₄, 10 HEPES, 2 MgCl₂, 0.1 CaCl₂, 1.1 EGTA, 2 Na-ATP, and 0.3 Na-GTP, 0.2% neurobiotin (Vector Laboratories, Burlingame, CA, USA, cat.# SP-1120; MW323; gap junction-permeable dye), and 0.04% dextran Alexa Fluor 594 (Invitrogen, cat.# D22913; MW10,000; gap junction-impermeable dye) (pH 7.2, 3–7 M Ω electrode resistance). Cells were patched using Multiclamp 700-B amplifier and pCLAMP10 software (Molecular Devices, Sunnyvale, CA, USA). *In slices*: On the day of preparation, slices were randomly numbered and the number and condition (a drug treatment) were documented in a database (Access) for later identification. Magnocellular neurons in the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON) were labeled after initial identification based on their location, size, and electrophysiological properties (Arumugam et al., 2005). Only one neuron per slice was labeled as reported (Arumugam et al., 2005). After labeling, the slices were fixed, processed, and stained with fluorescein avidin D (FITC, 1:200, Vector Laboratories). Alexa 594 fluorescence and neurobiotin staining were visualized using, respectively, Texas Red and FITC filters in Nikon 80i fluorescent microscope, PHOTOMETRICS ES2 camera and OpenLab Software (Improvision, Lexington, MA, USA). The incidence of gap junction coupling was analyzed blindly for experimental groups as described (Arumugam et al.,

2005). *In cultures*: Because different cell types are morphologically indistinguishable and electrophysiological characterization of cell types is not elaborated, neurons in cultures were chosen randomly. Neurons were labeled, stained, and analyzed as described above for slices.

Electrotonic coupling

To determine electrotonic coupling, dual whole-cell current-clamp recordings were conducted in cultures from pairs of randomly-chosen neurons. Test current steps (500 ms, -100 pA) were applied to cell 2 (injected cell) and electrotonic responses were detected in cell 1 (non-injected cell). Recordings were done at a holding potential of -65 mV. Data were monitored using an electrophysiology approach (see above) and analyzed off-line with Clampfit 10 (Molecular Devices). The coupling coefficient was calculated as the response amplitude in the non-injected cell (cell 1) divided by the amplitude in the injected cell (cell 2). Cells were considered as coupled if the coupling coefficient was above 1.6%.

Western blots

Experiments were performed as reported in detail (Arumugam et al., 2005). Briefly, hypothalamic tissue or cultured cells were homogenized in a lysis buffer and total protein was determined using the Bio-Rad DC protein assay method. Fifty μ g of protein was loaded in each lane, transferred to 0.45 μ m Polyvinylidene difluoride membrane and processed with a blocking solution and antibodies. Rabbit anti-Cx36 (0.5 μ g/ml; Zymed, San Francisco CA, USA, cat.# 51-6300), rabbit anti-Cx43 (0.2 μ g/ml; Zymed, cat.# 71-0700), rabbit anti-mGluR2 (0.5 μ g/ml; Millipore, Billerica, MA, USA, cat.# AB9209), rabbit anti-mGluR3 (0.5 μ g/ml; Sigma, St. Louis, MO, USA, cat.# G1545), mouse anti-Tubulin (1:10,000; Sigma, cat.# T6793) and rabbit anti-GAPDH (1:10,000; Cell Signaling Technology, Danvers, MA, USA, cat.# 2118) were used as the primary antibodies and they were visualized with horseradish peroxidase conjugated anti-rabbit (1:10,000, Zymed, cat.# G21234) or anti-mouse (1:10,000, Zymed, cat.# G21040) antibodies. Signals were enhanced using ECL detection reagents (Amersham Biosciences, Piscataway, NJ, USA). Band optical density was determined by using Quantity One quantification analysis software 4.5.2 (Bio-Rad, Hercules, CA, USA). All optical density signals were normalized relative to tubulin or GAPDH, and experimental samples were compared to controls (set at 1.0). Tubulin and GAPDH levels per unit of total protein did not vary significantly among samples used in this study.

siRNA

The mGluR2, mGluR3 and Cx36 siRNAs were purchased from Dharmacon RNAi Technologies (Lafayette, CO, USA; cat.# M-080176-00, L-094437-01 and L-090683-00, respectively). Each siRNA consisted of four pooled 19-nucleotide duplexes and was used in a final concentration of 50 nM. mGluR2 and mGluR3 siRNA transfections were performed on day *in vitro* 3 (DIV3) by using Lipofectamine 2000 (Invitrogen) and cells were processed on DIV7 for western blot analysis. Cx36 siRNA transfections were conducted on DIV10 and dye coupling was analyzed on DIV15. All transfections effectively reduced protein levels. Scrambled siRNAs were used as controls and were ineffective.

Reverse transcription-quantitative real time polymerase chain reaction (RT-qPCR)

Experiments were performed as reported (Al-Kandari et al., 2007). Total RNA was isolated from cultures using Trizol method (Invitrogen). Total RNA (1 μ g) was reverse transcribed with oligo-dT primers and the SuperScript II kit (Invitrogen) according to the manufacturer's instructions. One μ l of the reverse transcription reaction material was used as template for RT-qPCR using a Bio-Rad iCycler in a total volume of 20 μ l with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and amplified for 40 cycles

for 15 sec at 95°C and for 20 sec at 60°C. The following primer pairs were used: rat Cx36, 5'-CTATGTGTGAAAGGGCAGGTT-3' (sense) and 5'-AGCACTACGCAAATGAGGGCAA-3' (antisense); rat GAPDH, 5'-CAAGGCTGTGGGCAAGGTCAT-3' (sense) and 5'-GCAGGTTTCTCCAGGCGGCAT-3' (antisense). RT-qPCR was performed using at least 4 separately prepared sets of culture samples. For each sample set, Cx36 mRNA signals were normalized to GAPDH mRNA signals, and normalized values were compared to controls (set at 1.0).

Luciferase reporter activity analysis

Rat Cx36 gene promoter fragments were PCR-amplified from -984 to +115 relative to the transcription start site of the Cx36 gene (GeneID 50564, official name Gjd2) from a rat bacterial artificial chromosome containing the gene. Primers used were as follows: 5'-GCGAGATCTCGCTGTGCATCCGGAGGCAGC-3' for the antisense primer, 5'-GCGGCTAGCCCCTGGTTCGCTGCTAGGCAC-3' for the sense primer. The PCR products digested with NheI and BglII were cloned into the luciferase reporter plasmid pGL3basic (Promega, Madison, WI, USA). Site-directed mutagenesis was performed to produce an NRSE deleted plasmid using the Transformer Site-Directed Mutagenesis Kit (Clontech Inc. Palo Alto, CA) and the following primers: 5'-TAAATCGATAAGGGTCCGTCGACCGATGC-3' for selection primer and 5'-GAGACTGCGGGAGTCCGAGGTGCTGTCCAG-3' for mutagenic primer (the mutated nucleotide is underlined). The full length 3'-untranslated region (3'UTR) of the rat Cx36 mRNA (accession number NM 019281) was PCR-amplified using sense primer, 5'-TCGAGGATCCAAAGGGCAGGTTGGGGAAG-3' and antisense primer, 5'-GTTAGTCGACCAGGCCAAATGTCTGTCCAG-3'. The BamHI-SalI-digested products were cloned into the Cx36 promoter-containing pGL3basic vector replacing the SV40 poly A signal. All plasmid constructs were verified by sequencing. Cells were transfected on DIV3 using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's instructions. Some cultures were incubated (DIV4-DIV7) in the constant presence of receptor agonists and antagonists; cultures incubated in the absence of drugs served as a control. On DIV7, cell lysates were harvested and luciferase assay was performed with the DLR-Dual Luciferase kit (Promega) and Turner TD-20/20 Luminometer as described previously (Al-Kandari et al., 2007). All transfections for luciferase assay included an expression plasmid for *Renilla* luciferase. The firefly luciferase activity was normalized to *Renilla* luciferase activity, to account for variation in transfection efficiency.

Methyl thiazolyl tetrazolium (MTT) assay

Neuronal viability in cultures was quantitatively evaluated by MTT assay. Cultures were raised in 24-well plates. In all NMDA tests, NMDA was added to the culture medium on DIV14 (100 μ M for 60 min in hypothalamic cultures or 10 μ M for 30 min in cortical cultures) and then washed-out. LY341495- and LY379268-treated cultures were chronically (on DIV3-DIV15) incubated in the presence of these agents. Carbenoxolone was added to the culture medium on DIV14 (alone or together with NMDA) and remained in the medium until the end of the experiment (on DIV15). On DIV15, 24 hrs after NMDA wash-out, neurons were incubated with MTT (MTT cell Viability Assay Kit, Biotium, Inc.; Hayward, CA, USA; 40 μ M, 400 μ L per well) at 37°C for 4 hrs. Then the medium was carefully aspirated and 400 μ L of DMSO per well was added to dissolve the blue formazan product. To measure the absorbance, 200 μ L of the medium from each well in 24-well plate were transferred into an independent well in a 96-well plate. The values of absorbance at 570 nm were measured using a microplate reader (μ Quant, BioTek, Winooski, VT, USA). Further, as indicated above, cultures that are raised in Neurobasal medium contain mostly neurons (up to 95%). However, to control specifically for neuronal cell death, a separate group of cultures ($n = 6$) was subjected to a high concentration of glutamate (500 μ M) starting from

DIV14 for 24 hrs that killed all neurons, but did not affect glial cell survival. The absorbance in these purified glial cultures was measured, averaged, and the result was subtracted from the individual absorbance data in neuronal culture groups so that the final result would represent only neuronal death/survival. Finally, the absorbance results in experimental groups were normalized to control groups.

Drugs and reagents

All drugs were obtained from Sigma or Tocris (Ellisville, MO, USA) unless otherwise specified.

Statistical analysis

Data were analyzed using the two-tailed Student's *t*-test (paired, when possible), ANOVA or Fisher's exact probability test and InStat software (GraphPad Software, San Diego, CA, USA). Data are reported as mean \pm SEM for the number of samples indicated. Each date point represents indicated day \pm 1, except for siRNA and luciferase reporter activity experiments, where all dates are as indicated.

Results

Developmental increase in neuronal gap junction coupling *in vivo*

Developmental changes in neuronal gap junction coupling were determined in magnocellular neurons in acute slices of the PVN and SON of the rat hypothalamus. We utilized a dye coupling method (Arumugam et al., 2005) that included the use of two dyes: neurobiotin, which passes through gap junctions (coupling tracer), and dextran Alexa Fluor 594, which is gap junction impermeable (Fig. 1A–C). We also performed western analysis on dissected hypothalamus to confirm the dye coupling observations by measuring developmental changes in the expression of Cx36, a gap junction protein that is neuron-specific and is essential for functional gap junctions in the hypothalamus (Belluardo et al., 2000; Rash et al., 2000; Long et al., 2005) (Fig. 1F,G). The incidence of dye coupling, i.e. the percentage of primary-labeled neurons coupled to one or more secondary-labeled neurons, and the expression of Cx36 both increased between P1 and P15 (Fig. 1). This indicates a developmental increase in neuronal gap junction coupling in the hypothalamus. Daily (on P1–P15) subcutaneous administration of the group II mGluR agonist LY379268 augmented, and group II mGluR antagonist LY341495 prevented, these developmental increases in gap junction coupling and Cx36 expression (Fig. 1D,F,H and Table 1). In contrast, daily administration of the GABA_AR agonist muscimol prevented, and GABA_AR antagonist bicuculline augmented, the developmental increases in gap junction coupling and expression of Cx36 (Fig. 1E,G,I and Table 1) (see Materials and Methods for drug concentrations).

Developmental increase in neuronal gap junction coupling *in vitro*

A previous study in primary rat hypothalamic cultures indicated (Arumugam et al., 2005) that a developmental increase in neuronal gap junction coupling occurs during the first two weeks of *in vitro* development. This increase was prevented by blockade of action potentials (with 2 μ M tetrodotoxin, a voltage-gated sodium channel blocker), and was not affected by inactivation of NMDA receptors (NMDAR; with 100 μ M AP5). These results suggested that the developmental increase in neuronal gap junction coupling is regulated via action potential-dependent (synaptic) release of neurotransmitters, but NMDARs are not involved in this regulation.

In the present study, using neurobiotin with dextran Alexa Fluor 594 and western analysis we observed increases in neuronal dye coupling and Cx36 expression in developing rat

hypothalamic neuronal cultures between DIV3 and DIV15 (Fig. 2 and Table 1). In cultures, as in the hypothalamus *in vivo*, the developmental increases in dye coupling and Cx36 expression were augmented by the chronic (on DIV3-DIV15) activation of group II mGluRs with LY379268 (2 μ M) or DCG-IV (10 μ M; another group II mGluR agonist) and were prevented by inactivation of group II mGluRs with LY341495 (2 μ M) or EGLU (100 μ M; another group II mGluR antagonist) (Fig. 2D,F,H and Table 1; also see below Fig. 5A). Further, the developmental increases in gap junction coupling and the expression of Cx36 were prevented by activation of GABA_ARs with muscimol (25 μ M) or GABA (100 μ M) and were augmented by GABA_AR inactivation with bicuculline plus picrotoxin (100 μ M + 500 μ M; in these tests, ionotropic glutamate receptor antagonists, 100 μ M AP5 and 10 μ M CNQX, were co-administered with the GABA_AR antagonists to prevent an increase in glutamate-dependent activity) (Fig. 2E,G,I and Table 1). Similar results were obtained in cultures using electrotonic coupling analysis (Fig. 3). However, no difference in Cx36 expression was observed between the controls and cultures that were chronically treated (on DIV3-DIV15) with AP5 plus CNQX (100 μ M and 10 μ M), DHPG (10 μ M; group I mGluR agonist), AIDA (100 μ M; group I mGluR antagonist), PPG (10 μ M; group III mGluR agonist), MSOP (100 μ M; group III mGluR antagonist), nicotine (100 μ M; nicotinic acetylcholine receptor agonist), atropine plus mecamylamine (100 μ M each; muscarinic and nicotinic acetylcholine receptor antagonists), baclofen (20 μ M; GABA_B receptor agonist) or phaclofen (100 μ M; GABA_B receptor antagonist) (Fig. 4).

Taken together, our *in vivo* and *in vitro* data suggest that the developmental increase in gap junction coupling in hypothalamic neurons is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. In addition, group I mGluR, group III mGluR, NMDA, non-NMDA, acetylcholine and GABA_B receptors are not involved in these regulatory mechanisms.

Cellular mechanisms for developmental increase in gap junction coupling

Signaling pathways for group II mGluRs and GABA_ARs are well-characterized. Group II mGluRs (that include mGluR2 and mGluR3) negatively regulate cAMP/PKA (cAMP-dependent protein kinase)-dependent signaling (De Blasi et al., 2001; Conn et al., 2005). GABA_AR is a Cl⁻-permeable ion channel. In mature neurons, an activation of GABA_ARs causes Cl⁻ influx and cell hyperpolarization; in developing neurons, an activation of GABA_ARs causes an efflux of Cl⁻ ions and cell depolarization that results in a Ca²⁺ influx through voltage-gated Ca²⁺ channels (VGCC) and activation of Ca²⁺-dependent protein kinases (Stein and Nicoll, 2003). In primary rat hypothalamic cultures, GABA_AR-mediated responses are excitatory during the first 1–2 weeks of development and then the excitation is replaced by inhibitory responses (Obrietan and van den Pol, 1995).

To determine whether group II mGluRs and GABA_ARs regulate the developmental increase in neuronal gap junction coupling via, respectively, cAMP/PKA- and Ca²⁺-dependent signaling pathways, we performed additional pharmacological manipulations in rat hypothalamic cultures on DIV3-DIV15 and detected Cx36 expression by western analysis (Fig. 5). An increase in cytoplasmic levels of cAMP (by 8-Br-cAMP plus IBMX; 100 μ M + 50 μ M; a cell-permeable analog of cAMP that activates PKA and a non-specific phosphodiesterase inhibitor that increases intracellular cAMP levels) reduced, and the blockade of PKA (by H89; 1 μ M; PKA antagonist) augmented, the developmental increase in Cx36 expression (Fig. 5A). Further, the effects of group II mGluR agonist and antagonist in the developmental regulation of Cx36 (see Fig. 2) were prevented, respectively, by the increase in cAMP levels and inactivation of PKA (Fig. 5A).

The developmental increase in Cx36 expression also was prevented by KCl {1–5 mM; that causes cell depolarization and Ca²⁺ influx through L-type VGCCs (Bessho et al., 1994)} and

was augmented by the blockade of protein kinase C (PKC; with GF 109203X; 0.5–1 μM) (Fig. 5B). Further, the effect of the GABA_AR agonist, muscimol (25 μM), was prevented by blockade of L-type VGCCs with nifedipine (10 μM) or PKC inactivation (Fig. 5B), while the effect of GABA_AR antagonists (see Fig. 2) was prevented by activation of PKC (with phorbol 12-myristate 13-acetate, PMA; 1 μM) (Fig. 5B). However, the developmental increase in Cx36 expression was not affected by inactivation of another calcium-regulated protein kinase, Ca²⁺/calmodulin-dependent protein kinase II (CaMKII; with KN-62; 2.5 μM ; Fig. 5B).

These data suggest that the developmental regulation of Cx36 by group II mGluRs is via cAMP/PKA-dependent signaling; by GABA_ARs is via Ca²⁺/L-type VGCC/PKC-dependent signaling; and that CaMKII is not involved in control of the developmental increase in Cx36 expression.

The roles of mGluR2 vs. mGluR3 and group II mGluRs vs. GABA_ARs

We used an siRNA approach in rat hypothalamic cultures to determine the importance of mGluR2 vs. mGluR3 in the developmental increase in expression of Cx36 (Fig. 6A,B). The genetic suppression of both mGluR2 and mGluR3 (on DIV3-DIV7) decreased Cx36 protein levels, suggesting that both receptors are important for the developmental increase in neuronal gap junction coupling.

We also tested the importance of group II mGluRs vs. GABA_ARs (Fig. 6C). Rat hypothalamic cultures were chronically treated (on DIV3-DIV15) with LY379268 (2 μM) and muscimol (25 μM). A combined activation of group II mGluRs and GABA_ARs did not affect significantly the developmental up-regulation of Cx36. However, the effect of activating GABA_ARs dominated the effect of activating group II mGluRs: on DIV15, the expression of Cx36 was not different between muscimol-treated and LY379268 plus muscimol-treated cultures, but it was significantly different between LY379268-treated and LY379268 plus muscimol-treated cells (Fig. 6C). These data are in agreement with the observation that, in cell cultures on DIV3-DIV15, blockade of GABA_ARs increases Cx36 expression to a higher level than activation of group II mGluRs (2.64±0.35 vs. 1.81±0.20 normalized optical density; $P = 0.045$; unpaired Student's *t*-test; $n = 6$ in each group; see Fig. 2H,I).

Specificity of the mechanisms for increase in gap junction coupling

We tested whether the regulation by group II mGluRs and GABA_ARs is specific for neuronal Cx36-containing gap junctions. First, we found that the developmental increase in neuronal dye coupling in rat hypothalamic cultures is prevented by Cx36 siRNA (transfected on DIV10 and tested on DIV15; Table 1). Second, neuronal dye coupling was measured in hypothalamic cultures prepared from wild-type and Cx36 knockout mice. As expected, in wild-type cultures, the coupling was observed on DIV15 and was increased by both LY379268 and bicuculline plus picrotoxin (in the presence of AP5 and CNQX; in concentrations as in rat cultures; Fig. 6D and Table 1). However, the coupling was not observed in Cx36 knockout cultures, whether untreated or treated (Fig. 6D and Table 1). Moreover, in the rat hypothalamus *in vivo* and *in vitro*, the expression of a presumptive astrocytic connexin, connexin 43 {Cx43; (Rash et al., 2000)}, was not different between the control and the treatment conditions, including the treatments with group II mGluR and GABA_AR agonists and antagonists (Fig. 7). The data suggest that the group II mGluR/GABA_AR-dependent regulation is specific for neuronal Cx36-containing, but not glial Cx43-containing gap junctions. Moreover, this regulation is exclusive for Cx36 as no increase in gap junction coupling occurs in Cx36-deficient neurons.

We also examined whether these developmental mechanisms operate in other CNS regions and species and whether they are active in mature neurons. The activity of group II mGluRs and GABA_ARs was pharmacologically modulated (on DIV3-DIV15) in developing neuronal cultures prepared from the mouse somatosensory cortex, and western analysis of Cx36 expression revealed changes that were similar to those in rat hypothalamic cultures (Fig. 8). This suggests that the same regulatory mechanisms are employed in the developing mouse cortex and rat and mouse hypothalamus. Further, we tested mature cultures prepared from the rat hypothalamus. In these cultures, chronic (DIV30-DIV36) activation of group II mGluRs (with LY379268), but not inactivation of GABA_ARs (with bicuculline plus picrotoxin, in the presence of AP5 and CNQX; in concentrations as above), increased the expression of Cx36 (Fig. 9). Similar results were obtained in mature cultures prepared from the mouse cortex (not shown). These data suggest that the group II mGluRs may contribute to the up-regulation of neuronal gap junction coupling in mature neurons, though GABA_ARs, that are inhibitory in the mature CNS (Obrietan and van den Pol, 1995; Stein and Nicoll, 2003), presumably do not regulate the coupling after neuronal maturation. {The receptor-mediated inhibition of Cx36 expression was not tested as the expression of Cx36 is low in mature neuronal cultures (Arumugam et al., 2005)}.

Molecular mechanisms for developmental increase in gap junction coupling

In response to either group II mGluR activation or GABA_AR inactivation Cx36 protein levels increase during development and we tested whether this is associated with increased Cx36 mRNA. The expression of Cx36 mRNA was evaluated in rat hypothalamic cultures by RT-qPCR (Fig. 10A). We observed an increase in Cx36 mRNA levels between DIV3 and DIV15. Further, this increase was augmented by both activation of group II mGluRs (with LY379268) and inactivation of GABA_ARs (with bicuculline plus picrotoxin in the presence of AP5 and CNQX; in concentrations as above). However, the increase was not affected by both inactivation of group II mGluRs (with LY341495) and activation of GABA_ARs (with muscimol). The data suggest that the receptor-regulated increase, but not the decrease, in Cx36 expression during development may be controlled by transcriptional mechanisms.

Based on RT-qPCR experiments, we set to determine if an element within the Cx36 proximal promoter is responsible for the developmental increase in Cx36 mRNA levels (Fig. 10B). Cultures were transfected (on DIV3) with a plasmid containing the rat Cx36 promoter linked to the firefly luciferase gene and treated (on DIV4-DIV7) with the group II mGluR and GABA_AR agonists and antagonists. On DIV7, cells were harvested and luciferase assay was performed. The Cx36 proximal promoter (−984/+115) supported robust transcription. As in RT-qPCR experiments, the Cx36 promoter activity was augmented by activation of group II mGluRs and inactivation of GABA_ARs, and was not affected by LY341495 and muscimol. The increases in Cx36 promoter activity were completely abolished by deletion of an NRSE located at nucleotide position −164/−144 (Martin et al., 2003). In addition, NRSE deletion increased the basal expression of Cx36 promoter (Fig. 10B). The data suggest that NRSE has a repressive effect on Cx36 promoter activity and this repression is removed by activation of group II mGluRs or inactivation of GABA_ARs.

Next, we conducted experiments to determine whether the mechanism for the receptor-mediated decrease in Cx36 expression during development involves post-transcriptional regulation (Fig. 10B). We constructed the plasmid containing the full length Cx36 3'UTR (~1.5kb) and the luciferase reporter driven by the Cx36 promoter (−984/+115). Whereas this construct demonstrated reduced luciferase activity (as compared to the plasmid containing the Cx36 promoter alone), it showed not only significant increases, but also decreases in response to the treatments that, respectively, increase (group II mGluR agonists and GABA_AR antagonists) or decrease (group II mGluR antagonists and GABA_AR agonists) Cx36 protein expression (Fig. 10B). Together, the results indicate that the mechanisms that

orchestrate the developmental changes in Cx36 expression involve both the Cx36 promoter-mediated transcriptional regulation through NRSE and regulatory events mediated via the 3'UTR, perhaps involving post-transcriptional mechanisms.

Functional implications

Our previous study demonstrated (de Rivero Vaccari et al., 2007) that neuronal gap junctions play a critical role in the mechanisms of neuronal death/survival during development. Specifically, in rat and wild-type mouse hypothalamic neuronal cultures, we found that hyperactivation or inactivation of NMDARs both induced neuronal death exclusively during the peak of developmental gap junction coupling (i.e., on DIV14-17). Further, both types of NMDAR-dependent neuronal death were completely prevented by pharmacological inactivation of gap junctions (with carbenoxolone and 18 α -glycyrrhetic acid) or genetic knockout of Cx36. In the present study, we set to determine whether manipulation of the mechanisms regulating the developmental increase in neuronal gap junction coupling affects the death/survival mechanisms in developing neurons. We used a model of NMDAR-dependent excitotoxicity. Experiments were conducted in rat hypothalamic cultures, non-treated or chronically treated (on DIV3-15) with the group II mGluR agonist (LY379268) or antagonist (LY341495; in concentrations as above). Administration of NMDA (100 μ M; on DIV14 for 60 min) induced significant neuronal death in non-treated cultures that was detected 24 hrs later (on DIV15) using MTT assay (Fig. 11A). NMDA-mediated neuronal death was more pronounced in LY379268-treated cultures, i.e., in the cultures with high levels of neuronal gap junction coupling and Cx36 expression. Further, NMDA-mediated neuronal death was not observed in LY341495-treated cultures, i.e., in the cultures that lack neuronal gap junction coupling due to low levels of Cx36. NMDA-mediated neuronal death also was prevented by the gap junction blocker carbenoxolone (25 μ M; Fig. 11B), supporting the notion that gap junctions participate in NMDAR-dependent death in developing neurons. Similar results were obtained in wild-type mouse cortical neuronal cultures (not shown). The results indicate that the mechanisms for the developmental increase in neuronal gap junction coupling play a role in regulation of neuronal death/survival during development.

Discussion

We demonstrated here that the developmental increase in neuronal gap junction coupling in the rat and mouse hypothalamus and cortex is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. The regulation by group II mGluRs is via cAMP/PKA-dependent signaling. The regulation by GABA_ARs, which cause neuronal excitation during development (Obrietan and van den Pol, 1995; Stein and Nicoll, 2003), is via Ca²⁺ influx through VGCCs and activation of PKC. We also showed that other glutamate receptors, acetylcholine receptors, GABA_B receptors and CaMKII are not involved in these regulatory mechanisms. A previous study in the rat hypothalamus indicated (Arumugam et al., 2005) that blockade of action potentials prevents the developmental increase in neuronal gap junction coupling. Together with the results described here, this implicates a role for action potential-dependent synaptic release of glutamate and GABA in regulation of the developmental increase in neuronal gap junction coupling.

Group II mGluRs include mGluR2 and mGluR3, and our experiments suggested that both of them are important for the developmental increase in neuronal gap junction coupling. Data also indicated that the effects of GABA_AR agents in modulation of gap junctions are stronger than those of group II mGluR agents. This supports a more important role for GABA_ARs than group II mGluRs in these regulatory mechanisms, which may be explained by the fact that formation of GABAergic synapses in the CNS precedes the formation of glutamatergic synapses (Ben-Ari, 2002). It is possible, however, that the pattern of

expression of particular neurotransmitter receptors and timing of the switch of GABA_ARs from excitation to inhibition during development determine when the developmental increase in neuronal gap junction coupling occurs. Future experiments are needed to evaluate this prediction.

Cx43 is a presumptive glial connexin (Rash et al., 2000), that also is involved in a number of developmental events, including neuronal migration (Elias et al., 2007). Our study showed that the expression of Cx43, a presumptive glial connexin, also increases during development, however, the increase is not affected by the group II mGluR and GABA_AR agents. This suggests that the regulation by group II mGluRs and GABA_ARs is specific for Cx36-containing, but not Cx43-containing gap junctions. Moreover, this regulation is exclusive for Cx36 as no increase in gap junction coupling (either developmental or treatment-mediated) occurs in Cx36-deficient neurons (Fig. 6D).

NRSE is a DNA sequence element in a promoter region of a number of neuronal genes that binds RE1-silencing transcription factor (REST) and regulates the transcriptional activity of these genes. REST activity is influenced by both Ca²⁺- and cAMP-dependent signaling (Nadeau and Lester, 2002; Somekawa et al., 2009). Rat and mouse Cx36 genes contain NRSEs (-164/-144 and +201/+221, respectively) (Cicirata et al., 2000; Martin et al., 2003) and occupancy of the Cx36 NRSE by REST is observed in mouse neuronal stem cells (Johnson et al., 2008). Further, REST/NRSE-dependent signaling negatively regulates Cx36 mRNA expression in insulin-producing cells (Martin et al., 2003). Our study in developing hypothalamic neurons agrees with those findings and demonstrates that deletion of the NRSE in Cx36 promoter region results in both higher basal transcription and loss of responsiveness to the group II mGluR agonist and GABA_AR antagonists. Thus, the data suggest that the receptor-mediated increase in Cx36 expression during development is regulated by group II mGluRs and GABA_ARs via removal of the NRSE-dependent repression of Cx36 promoter activity.

In contrast, the mechanisms for the receptor-mediated decrease in expression of Cx36 during development may not be due to new mRNA synthesis; rather involving post-transcriptional mechanisms dependent upon sequences within the 3'-UTR. While we cannot totally rule out the presence of a transcriptional regulatory element in the region of 3'UTR, given that the Cx36 mRNA levels did not change in response to inactivation of group II mGluRs or activation of GABA_ARs, this possibility seems unlikely. Rather, we suspect that this regulation may be via microRNAs, small non-coding RNAs, which bind to complementary sites on 3'UTR of target mRNAs and reduce gene expression primarily through translational repression (Bartel, 2004). Many microRNAs are brain-specific (Sempere et al., 2004) and are involved in the regulation of neuronal development, differentiation and morphogenesis (Smirnova et al., 2005; Vo et al., 2005). The 3'UTR of Cx36 mRNA contains binding sites for a number of brain-specific microRNAs, including miR-9, miR-128a and miR-128b (Rash et al., 2005). A focus of future studies will be to identify which, if any, of these miRNAs target Cx36 and to determine the specific signals that regulate their action.

During pharmacological manipulations, changes occur not only in the incidence of dye and electrotonic coupling, but also in the coupling coefficient. Together with data demonstrating alterations in Cx36 protein expression, these results suggest the possibility of adding/removing Cx36 molecules to/from individual neurons.

We also postulate that group II mGluR and GABA_AR agonists and antagonists exert specific, physiological effects on neuronal gap junction coupling. First, the agents modulate the developmental increases in the coupling and Cx36 expression in a similar way *in vivo* and *in vitro*. Second, the increases are modulated not only by receptor agonists and

antagonists, but also by manipulating the corresponding receptor-coupled intracellular signaling. Third, it is unlikely that the effects are simply through the regulation of electrical activity as the developmental increases in coupling and/or Cx36 expression are prevented both by tetrodotoxin (that reduces the action potential activity)(Arumugam et al., 2005) and by KCl (that depolarizes neurons and increases the action potential activity)(Fig. 5B). Finally, the developmental increase in Cx36 is affected not only by pharmacological treatments, but also by genetic manipulations for the expression of mGluR2 and mGluR3.

A previous study demonstrated a role for glutamate-dependent synaptic transmission in the developmental uncoupling of neuronal gap junctions (that occurs in the hypothalamus between days 15 and 30 *in vivo* and *in vitro*)(Arumugam et al., 2005). The data indicated that developmental uncoupling is due to activation of NMDARs and Ca²⁺-, CaMKII-, PKC- and CREB (Ca²⁺/cAMP response element binding protein)-dependent down-regulation of Cx36. Together with the present work, our studies strongly suggest that developing chemical synapses regulate electrical synapses. We postulate that during early postnatal development, GABA_AR-dependent excitation maintains the expression of Cx36 in neuronal circuits at a low level (via Ca²⁺/PKC signaling and 3'UTR of the Cx36 mRNA). The subsequent transition from GABA_AR excitation to inhibition, in combination with increased activity of the group II mGluRs, result in the developmental up-regulation of Cx36 (via the NRSE in the Cx36 gene) and increased neuronal gap junction coupling. However, the developmental increase in the activity of NMDARs then causes down-regulation of Cx36 (via Ca²⁺-dependent signaling, including CREB) and gap junction uncoupling. If mechanisms for the developmental regulation of gap junctions have universal character in the CNS (as we show here for the hypothalamus and cortex), the variations among different CNS regions in the timing of neuronal gap junction coupling and uncoupling (Bennett and Zukin, 2004) presumably can be explained by the interregional differences in the activity of these mechanisms (i.e., receptor and synaptic activity and timing of the excitation/inhibition switch for GABA_ARs). Other additional, region-specific factors probably also contribute.

In the developing and mature CNS, neuronal gap junction coupling also may be modulated acutely by changes in the activity of neurotransmitter receptors (Hatton, 1998). We believe that acute and developmental alterations in the coupling represent different functional aspects of gap junction physiology. The acute modulation of gap junctions by neurotransmitter receptors likely involves gating mechanisms and plays a role in rapid modifications in neuronal connectivity and signaling in response to changes in chemical synaptic activity (Hatton, 1998). In contrast, the developmental changes in gap junctions likely are related to specific genetic programs and/or developmental pathways during the period when chemical synapses are still being established. It is possible, however, that the acute modulation of coupling may translate into a prolonged modification if the changed level of receptor activity sustains.

In the developing CNS, programmed cell death helps to establish the final number of neurons and contributes to distribution of various cell classes and neuronal circuit formation (Nijhawan et al., 2000). The activity of NMDARs also is the factor that plays a role in cell survival versus death decisions during neuronal development (Scheetz and Constantine-Paton, 1994; de Rivero Vaccari et al., 2006). It has been suggested that during development gap junctions are involved in the regulation of apoptosis and NMDAR-dependent neuronal death (Cusato et al., 2003; de Rivero Vaccari et al., 2007). We showed here that the NMDAR-mediated excitotoxicity is eliminated or augmented if the amount of gap junctional coupling is reduced or increased, respectively. This suggests that mechanisms for the developmental increase in neuronal gap junction coupling directly regulate death/survival mechanisms in developing neurons. This also implies a role for gap junctions in formation of neuronal circuits via regulation of neuronal death/survival.

In conclusion, we have characterized the mechanisms for developmental increase in neuronal gap junction coupling. The coupling also increases in the mature CNS during neuronal injuries (Chang et al., 2000; Frantseva et al., 2002; de Pina-Benabou et al., 2005; Nemani and Binder, 2005; Thalakoti et al., 2007), and selective blockade of Cx36-containing gap junctions is neuroprotective (Wang et al., 2010). Given that neuronal injuries are characterized by excessive release of glutamate (Arundine and Tymianski, 2004) and that activation of group II mGluRs increases Cx36 expression in mature neurons (present study), it will be interesting to see whether mechanisms for the injury-related increases in neuronal gap junction coupling are group II mGluR-dependent and whether inactivation of these mechanisms has a neuroprotective effect.

Acknowledgments


We are grateful to Drs. D. Paul and M. Feller for providing us with the Cx36 knockout mice. This research was supported by NIH (R01 NS064256 and R01 DA015088), NIH/NCRR (P20 RR024214), Kansas IDeA Network of Biomedical Research Excellence (K-INBRE) and the University of Kansas Medical Center funds to A.B.B. and by the Biomedical Research Training Program award to Y.W. Core support was provided by NIH HD002528.

References

- Al-Kandari W, Jambunathan S, Navalgund V, Koneni R, Freer M, Parimi N, Mudhasani R, Fontes JD. ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription. *Mol Immunol.* 2007; 44:311–321. [PubMed: 16600381]
- Allen F, Warner A. Gap junctional communication during neuromuscular junction formation. *Neuron.* 1991; 6:101–111. [PubMed: 1986772]
- Arumugam H, Liu X, Colombo PJ, Corriveau RA, Belousov AB. NMDA receptors regulate developmental gap junction uncoupling via CREB signaling. *Nat Neurosci.* 2005; 8:1720–1726. [PubMed: 16299502]
- Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. *Cell Mol Life Sci.* 2004; 61:657–668. [PubMed: 15052409]
- Bani-Yaghoob M, Underhill TM, Naus CC. Gap junction blockage interferes with neuronal and astroglial differentiation of mouse P19 embryonal carcinoma cells. *Dev Genet.* 1999; 24:69–81. [PubMed: 10079512]
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004; 116:281–297. [PubMed: 14744438]
- Belluardo N, Mudo G, Trovato-Salinaro A, Le Gurun S, Charollais A, Serre-Beinier V, Amato G, Haefliger JA, Meda P, Condorelli DF. Expression of connexin36 in the adult and developing rat brain. *Brain Res.* 2000; 865:121–138. [PubMed: 10814742]
- Belousov AB, van den Pol AN. Local synaptic release of glutamate from neurons in the rat hypothalamic arcuate nucleus. *J Physiol (Lond).* 1997; 499:747–761. [PubMed: 9130170]
- Belousov AB, O'Hara BF, Denisova JV. Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus *in vitro* in the absence of glutamate excitation. *J Neurosci.* 2001; 21:2015–2027. [PubMed: 11245685]
- Ben-Ari Y. Developing networks play a similar melody. *Trends Neurosci.* 2001; 24:353–360. [PubMed: 11356508]
- Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. *Nat Rev Neurosci.* 2002; 3:728–739. [PubMed: 12209121]
- Bennett MV, Zukin RS. Electrical coupling and neuronal synchronization in the Mammalian brain. *Neuron.* 2004; 41:495–511. [PubMed: 14980200]
- Bessho Y, Nawa H, Nakanishi S. Selective up-regulation of an NMDA receptor subunit mRNA in cultured cerebellar granule cells by K(+)-induced depolarization and NMDA treatment. *Neuron.* 1994; 12:87–95. [PubMed: 8292362]
- Chang Q, Pereda A, Pinter MJ, Balice-Gordon RJ. Nerve injury induces gap junctional coupling among axotomized adult motor neurons. *J Neurosci.* 2000; 20:674–684. [PubMed: 10632597]


- Cicirata F, Parenti R, Spinella F, Giglio S, Tuorto F, Zuffardi O, Gulisano M. Genomic organization and chromosomal localization of the mouse Connexin36 (mCx36) gene. *Gene*. 2000; 251:123–130. [PubMed: 10876089]
- Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. *Nat Rev Neurosci*. 2005; 6:787–798. [PubMed: 16276355]
- Cusato K, Bosco A, Rozental R, Guimaraes CA, Reese BE, Linden R, Spray DC. Gap junctions mediate bystander cell death in developing retina. *J Neurosci*. 2003; 23:6413–6422. [PubMed: 12878681]
- De Blasi A, Conn PJ, Pin J, Nicoletti F. Molecular determinants of metabotropic glutamate receptor signaling. *Trends Pharmacol Sci*. 2001; 22:114–120. [PubMed: 11239574]
- de Pina-Benabou MH, Szostak V, Kyrozis A, Rempe D, Uziel D, Urban-Maldonado M, Benabou S, Spray DC, Federoff HJ, Stanton PK, Rozental R. Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. *Stroke*. 2005; 36:2232–2237. [PubMed: 16179575]
- de Rivero Vaccari JC, Corriveau RA, Belousov AB. Gap junctions are required for NMDA receptor-dependent cell death in developing neurons. *J Neurophysiol*. 2007; 98:2878–2886. [PubMed: 17855590]
- de Rivero Vaccari JC, Casey GP, Aleem S, Park WM, Corriveau RA. NMDA receptors promote survival in somatosensory relay nuclei by inhibiting Bax-dependent developmental cell death. *Proc Natl Acad Sci U S A*. 2006; 103:16971–16976. [PubMed: 17077143]
- Elias LA, Wang DD, Kriegstein AR. Gap junction adhesion is necessary for radial migration in the neocortex. *Nature*. 2007; 448:901–907. [PubMed: 17713529]
- Feller MB, Wellis DP, Stellwagen D, Werblin FS, Shatz CJ. Requirement for cholinergic synaptic transmission in the propagation of spontaneous retinal waves. *Science*. 1996; 272:1182–1187. [PubMed: 8638165]
- Frantseva MV, Kokarotseva L, Naus CG, Carlen PL, MacFabe D, Perez Velazquez JL. Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury. *J Neurosci*. 2002; 22:644–653. [PubMed: 11826094]
- Hatton GI. Synaptic modulation of neuronal coupling. *Cell Biol Int*. 1998; 22:765–780. [PubMed: 10873290]
- Johnson R, Teh CH, Kunarso G, Wong KY, Srinivasan G, Cooper ML, Volta M, Chan SS, Lipovich L, Pollard SM, Karuturi RK, Wei CL, Buckley NJ, Stanton LW. REST regulates distinct transcriptional networks in embryonic and neural stem cells. *PLoS Biol*. 2008; 6:e256. [PubMed: 18959480]
- Kandler K, Katz LC. Coordination of neuronal activity in developing visual cortex by gap junction-mediated biochemical communication. *J Neurosci*. 1998; 18:1419–1427. [PubMed: 9454851]
- Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S, Nedergaard M. Gap-junction-mediated propagation and amplification of cell injury. *Nat Neurosci*. 1998; 1:494–500. [PubMed: 10196547]
- Long MA, Jutras MJ, Connors BW, Burwell RD. Electrical synapses coordinate activity in the suprachiasmatic nucleus. *Nat Neurosci*. 2005; 8:61–66. [PubMed: 15580271]
- Martin D, Tawadros T, Meylan L, Abderrahmani A, Condorelli DF, Waeber G, Haefliger JA. Critical role of the transcriptional repressor neuron-restrictive silencer factor in the specific control of connexin36 in insulin-producing cell lines. *J Biol Chem*. 2003; 278:53082–53089. [PubMed: 14565956]
- Muller M, Gahwiler BH, Rietschin L, Thompson SM. Reversible loss of dendritic spines and altered excitability after chronic epilepsy in hippocampal slice cultures. *Proc Natl Acad Sci U S A*. 1993; 90:257–261. [PubMed: 8093558]
- Nadeau H, Lester HA. NRSF causes cAMP-sensitive suppression of sodium current in cultured hippocampal neurons. *J Neurophysiol*. 2002; 88:409–421. [PubMed: 12091564]
- Nemani VM, Binder DK. Emerging role of gap junctions in epilepsy. *Histol Histopathol*. 2005; 20:253–259. [PubMed: 15578443]
- Nijhawan D, Honarpour N, Wang X. Apoptosis in neural development and disease. *Annu Rev Neurosci*. 2000; 23:73–87. [PubMed: 10845059]

- Obrietan K, van den Pol AN. GABA neurotransmission in the hypothalamus: developmental reversal from Ca²⁺ elevating to depressing. *J Neurosci*. 1995; 15:5065–5077. [PubMed: 7623135]
- Peinado A, Yuste R, Katz LC. Extensive dye coupling between rat neocortical neurons during the period of circuit formation. *Neuron*. 1993; 10:103–114. [PubMed: 8427699]
- Personius K, Chang Q, Bittman K, Panzer J, Balice-Gordon R. Gap junctional communication among motor and other neurons shapes patterns of neural activity and synaptic connectivity during development. *Cell Commun Adhes*. 2001; 8:329–333. [PubMed: 12064613]
- Rash JE, Staines WA, Yasumura T, Patel D, Furman CS, Stelmack GL, Nagy JI. Immunogold evidence that neuronal gap junctions in adult rat brain and spinal cord contain connexin-36 but not connexin-32 or connexin-43. *Proc Natl Acad Sci U S A*. 2000; 97:7573–7578. [PubMed: 10861019]
- Rash JE, Davidson KG, Kamasawa N, Yasumura T, Kamasawa M, Zhang C, Michaels R, Restrepo D, Ottersen OP, Olson CO, Nagy JI. Ultrastructural localization of connexins (Cx36, Cx43, Cx45), glutamate receptors and aquaporin-4 in rodent olfactory mucosa, olfactory nerve and olfactory bulb. *J Neurocytol*. 2005; 34:307–341. [PubMed: 16841170]
- Saper, CB. Hypothalamus. In: Paxinos, G.; Mai, JK., editors. *The Human Nervous System*. 2. San Diego: Academic Press; 2004. p. 513-550.
- Scheetz AJ, Constantine-Paton M. Modulation of NMDA receptor function: implications for vertebrate neural development. *FASEB J*. 1994; 8:745–752. [PubMed: 8050674]
- Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol*. 2004; 5:R13. [PubMed: 15003116]
- Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation of miRNA expression during neural cell specification. *Eur J Neurosci*. 2005; 21:1469–1477. [PubMed: 15845075]
- Somekawa S, Imagawa K, Naya N, Takemoto Y, Onoue K, Okayama S, Takeda Y, Kawata H, Horii M, Nakajima T, Uemura S, Mochizuki N, Saito Y. Regulation of aldosterone and cortisol production by the transcriptional repressor neuron restrictive silencer factor. *Endocrinology*. 2009 E-publication ahead of print.
- Stein V, Nicoll RA. GABA generates excitement. *Neuron*. 2003; 37:375–378. [PubMed: 12575946]
- Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. *Headache*. 2007; 47:1008–1023. [PubMed: 17635592]
- Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. *Proc Natl Acad Sci U S A*. 2005; 102:16426–16431. [PubMed: 16260724]
- Walton KD, Navarrete R. Postnatal changes in motoneurone electrotonic coupling studied in the in vitro rat lumbar spinal cord. *J Physiol*. 1991; 433:283–305. [PubMed: 1668753]
- Wang X, Zheng H, Liu C, Zhu C, Wang W, Li Z. Ciliary neurotrophic factor-treated astrocyte conditioned medium regulates the L-type calcium channel activity in rat cortical neurons. *Neurochem Res*. 2008; 33:826–832. [PubMed: 17940876]
- Wang Y, Denisova JV, Kang KS, Fontes JD, Zhu BT, Belousov AB. Neuronal gap junctions are required for NMDA receptor-mediated excitotoxicity: implications in ischemic stroke. *J Neurophysiol*. 2010; 104:3551–3556. [PubMed: 20943940]

**Figure 1.**

Developmental increase in neuronal gap junction coupling in the rat hypothalamus *in vivo* is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. **A–C**, Images of neurobiotin (**A**, green) and dextran Alexa 594 (**B**, red) staining in an SON slice (P15; bicuculline-treated rat) are superimposed in **C** (shown at higher magnification). Yellow indicates dye colocalization in the primary-labeled neuron. Arrow indicates the secondary-labeled neuron. **D, E**, Incidence of dye coupling. Statistical significance was calculated using the Fisher's exact probability test (19–22 primary-labeled neurons per data point; data for SON and PVN are combined; also see Table 1). **F–I**, Expression of Cx36 protein in the hypothalamus. Optical density signals are normalized relative to tubulin and P15 saline-treated controls are set at 1.0. Statistical analysis (**H, I**): Student's *t*-test; mean ±

SEM; $n = 10$ in each group. In all graphs, statistical difference is shown relative to: (a), P1; (b), P15 saline; (c), LY379268; (d) bicuculline.

**Figure 2.**

Developmental increase in neuronal gap junction coupling in the rat hypothalamus *in vitro* is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. **A–C**, Images of neurobiotin (**A**) and dextran Alexa 594 (**B**) staining and their overlap (**C**) are shown (DIV15; culture treated with bicuculline, picrotoxin, AP5, and CNQX; Bic/PiTX+A/C). Yellow indicates dye colocalization in the primary-labeled neuron. Arrows indicate the secondary-labeled neurons. **D, E**, Incidence of dye coupling. Statistical significance was calculated using the Fisher's exact probability test (20–35 primary-labeled neurons per data point, also see Table 1). **F–I**, Expression of Cx36 protein. Optical density signals are normalized relative to tubulin and DIV15 controls are set at 1.0. Statistical analysis (**H, I**): Student's *t*-test; mean ± SEM; *n* = 6 in each group. In all graphs, statistical difference is shown relative to: (a), DIV3; (b), DIV15 control; (c), LY379268; (d) Bic/PiTX+A/C.




Figure 3.

Developmental increase in neuronal gap junction coupling is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. Data from electrotonic coupling experiments in rat hypothalamic cultures are presented. The coupling was determined as described in Materials and Methods. The number of coupled pairs was as follows: DIV3, 0 of 21; DIV15: Control, 6 of 28; LY379268, 8 of 15; LY341495, 1 of 32; muscimol, 0 of 22; Bic/PiTX+A/C, 10 of 19. **A, B**, Incidence of electrotonic coupling represents the percentage of neuronal pairs that demonstrated the coupling. Statistical significance: Fisher's exact probability test; (a) relative to DIV3; (b) relative to DIV15 control. **C**, Representative traces of electrotonic responses are shown (each trace is the average voltage response from 5 sequential steps). **D**, Statistical analysis of the coupling coefficient (see Materials and Methods): Student's *t*-test relative to DIV15 control; mean ± SEM (responses from all of the tested pairs are included in the analysis). Note, that on DIV15, the incidence of electrotonic coupling and the coupling coefficient both are higher (relative to the control) in cultures subjected to chronic activation of group II mGluRs and inactivation of GABA_ARs and are lower in cultures subjected to inactivation of group II mGluRs and activation of GABA_ARs.






Figure 4.

Ionotropic glutamate receptors, group I mGluRs, group III mGluRs, acetylcholine receptors and GABA_B receptors are not involved in the regulation of developmental increase in neuronal gap junction coupling. Pharmacological manipulations (see text for details and concentrations) were performed in rat hypothalamic cultures on DIV3-15 followed by assessment of Cx36 protein expression on DIV15. Optical density signals are normalized relative to tubulin, and normalized values are compared to the control (set at 1.0). Statistical data are presented: paired Student's *t*-test relative to control; mean \pm SEM; $n = 6$ in each group. No significant difference between the control and indicated treatments was found. A/C, AP5 plus CNQX; Atr/Mec, atropine plus mecamylamine.

**Figure 5.**

Signal transduction pathways. Pharmacological manipulations (see text for details) were performed in rat hypothalamic cultures on DIV3-DIV15 followed by assessment of Cx36 protein expression on DIV15. **A**, The regulation of Cx36 by group II mGluRs is through cAMP/PKA-dependent signaling. **B**, The regulation of Cx36 by GABA_ARs is through Ca²⁺/L-type VGCC/PKC-dependent signaling. CaMKII is not involved in the developmental regulation of Cx36. In both figures: above, statistical data; below, representative blots for cAMP/PKA- (**A**) and Ca²⁺/PKC-dependent (**B**) signaling are shown. Statistical analysis: paired Student's *t*-test; mean \pm SEM; *n* = 6 in each group. Optical density values are normalized to tubulin and compared to controls (set at 1.0). cAMP, 8-Br-cAMP plus IBMX; GFX, GF 109203X; NS, non-significant.

**Figure 6.**

Characterization of the mechanisms for developmental increase in neuronal gap junction coupling. Western blot (A–C) and dye coupling (D) tests were performed in neuronal cultures prepared from the rat (A–C) and mouse (D) hypothalamus. A, B, siRNA suppression (on DIV3–DIV7) of mGluR2 (A) and mGluR3 (B) decreases both the receptor and Cx36 protein levels. Representative images (above) and statistical data (below; paired Student's *t*-test relative to control; mean \pm SEM) are shown. Stainings were done sequentially on one membrane. SCR, scrambled siRNA. C, A combined activation (on DIV3–DIV15) of group II mGluRs and GABA_ARs (with LY379268 plus muscimol) does not affect significantly the developmental up-regulation of Cx36 expression. Statistical analysis: ANOVA with post hoc Tukey; (a), relative to DIV15 control; (b), relative to LY379268 plus muscimol; mean \pm SEM. D, In wild-type cultures, dye coupling increases

between DIV3 (not shown) and DIV15 (Control) and this increase is augmented by inactivation of GABA_ARs (Bic/PiTX+A/C) and by activation of group II mGluRs (LY379268). In Cx36 knockout cultures, neither the developmental nor the treatment-mediated increases occur. The number of dye-coupled primary-labeled neurons of the total number of primary-labeled neurons and statistical significance (Fisher's exact probability test; relative to the corresponding control) on DIV15 are shown. Pⁱ, P value cannot be calculated.




Figure 7. Group II mGluRs and GABA_ARs are not involved in the developmental regulation of hypothalamic expression of glial Cx43. Western blots for Cx43 (**A**, **B**, **D**, **E**) and statistical data (**C**, **F**) in the developing rat hypothalamus (**A–C**) and hypothalamic cultures (**D–F**) are presented. In **C** and **F**, statistical analysis is done using the paired Student's *t*-test relative to P15 saline or DIV15 control; mean ± SEM; *n* = 6 in each group. Data are normalized and analyzed as described in Fig. 1 and 2 for Cx36. Cx43 expression increases during development both *in vivo* and *in vitro*, however, the increase is not affected by group II mGluR and GABA_AR agonists or antagonists (i.e., no statistical significance between the saline/control and experimental groups on P15 or DIV15 is detected).




Figure 8.

Developmental increase in neuronal gap junction coupling in the mouse cortex *in vitro* is regulated by an interplay between the activity of group II mGluRs and GABA_ARs. **A, B**, Expression of Cx36 protein. Data are normalized and analyzed as described in Fig. 2. Statistical analysis: Student's *t*-test; (a), relative to DIV3; (b), relative to DIV15 control; mean \pm SEM; $n = 6$ in each group. Drug concentrations are as in experiments in rat hypothalamic cultures shown in Fig. 2.





Figure 9. Regulation of Cx36 expression in mature neurons. Pharmacological treatments were conducted in rat hypothalamic neuronal cultures on DIV30-DIV36 followed by assessment of Cx36 protein expression on DIV36. Statistical analysis: paired Student's *t*-test relative to control; mean \pm SEM; $n = 7$, LY3792688; $n = 5$, Bic/PiTX+A/C. Data are normalized and analyzed as described in Fig. 2.

**Figure 10.**

Molecular mechanisms for the developmental regulation of Cx36. **A**, RT-qPCR analysis in rat hypothalamic cultures demonstrates that Cx36 mRNA expression increases during development and this increase is augmented by activation of group II mGluRs (LY379268) and inactivation of GABA_ARs (Bic/PiTX+A/C). However, it is not affected by inactivation of group II mGluRs (LY341495) and activation of GABA_ARs (muscimol). Relative Cx36 transcript levels are normalized to GAPDH and normalized values are compared to DIV15 controls (set to 1.0). Statistical analysis: paired Student's *t*-test relative to control; mean \pm SEM. **B**, Dual-luciferase reporter assay. Cells were transfected on DIV3 with the luciferase (LUC) reporter plasmids driven by the rat Cx36 promoter (P_{Cx36}), incubated in the absence or in the presence of indicated agents and then assayed on DIV7. NRSE deleted plasmid was produced using site-directed mutagenesis. The plasmid containing Cx36 3'UTR was constructed by replacing the original SV40 poly A signal (SV40 pA) in the plasmid containing P_{Cx36} with the full length rat Cx36 3'UTR. Firefly luciferase values are normalized relative to Renilla luciferase values to control for transfection efficiency and the results are presented as relative activity of the promoter constructs compared to the pGL3basic vector (set to 1.0). Statistical analysis: paired Student's *t*-test relative to the corresponding non-treated control; mean \pm SEM.




Figure 11.

Mechanisms for the developmental increase in neuronal gap junction coupling play a role in regulation of neuronal death/survival during development. Experiments were conducted in rat hypothalamic neuronal cultures. NMDA (100 μ M) was added to the culture medium on DIV14 for 60 min and then washed-out. The MTT analysis of neuronal death was conducted 24 hrs later (on DIV15). **A**, NMDA administration induces neuronal death in non-treated cultures. NMDA-mediated neuronal death is augmented in cultures chronically treated (on DIV3-DIV15) with the group II mGluR agonist (LY379268) and does not occur in cultures chronically treated with the group II mGluR antagonist (LY341495). The mGluR agents by themselves do not affect cell survival. **B**, NMDA-mediated neuronal death also is prevented by co-administration of the gap junctional blocker carbenoxolone (CBX). In both graphs, statistical data are shown. Statistical analysis: ANOVA with post hoc Tukey; (a), relative to control; (b), relative to non-treated plus NMDA condition; mean \pm SEM; $n = 6$ in each group.

Table 1

Neuronal dye coupling in the hypothalamus *in vivo* and *in vitro*.

Conditions	Total number of primary-labeled neurons	Number of dye-primary-coupled labeled neurons, (%)	Coupling index ⁱ			
			1	2	3	4
Slice, rat ⁱⁱ						
PI	19	0 (0), P = 0.049	-	-	-	-
P15, saline	21	5 (23.8)	3	-	1	1
P15, bicuculline	21	10 (47.6), P = 0.197	6	3	1	-
P15, muscimol	19	0 (0), P = 0.049	-	-	-	-
P15, LY341495	22	0 (0), P = 0.021	-	-	-	-
P15, LY379268	21	9 (42.9), P = 0.326	6	3	-	-
Culture, rat ⁱⁱⁱ						
DIV3, control	32	0 (0), P = 0.024	-	-	-	-
DIV15, control	32	6 (18.8)	5	1	-	-
DIV15, Bic/PITX+A/C	25	11 (44.0), P = 0.047	10	1	-	-
DIV15, muscimol	35	1 (2.9), P = 0.048	1	-	-	-
DIV15, LY341495	24	0 (0), P = 0.032	-	-	-	-
DIV15, LY379268	20	6 (33.3), P = 0.500	4	2	-	-
DIV15, Cx36 siRNA	25	0 (0), P = 0.029	-	-	-	-
DIV15, SCR siRNA	21	4 (19.0), P = 1.0 ⁱⁱⁱ P = 0.037 ^{iv}	2	1	1	-
Culture, wild-type mouse ⁱⁱⁱ						
DIV15, control	26	3 (11.5)	2	1	-	-
DIV15, Bic/PITX+A/C	21	8 (38.1), P = 0.043	5	2	1	-
DIV15, LY379268	24	9 (37.5), P = 0.047	6	1	1	1
Culture, Cx36 knockout mouse ⁱⁱⁱ						
DIV15, control	20	0 (0)	-	-	-	-
DIV15, Bic/PITX+A/C	21	0 (0) ^v	-	-	-	-
DIV15, LY379268	21	1 (4.8), P = 1.0	1	-	-	-

ⁱ Coupling index is the number of secondary-labeled neurons coupled to the primary labeled neuron.

ⁱⁱ⁻ⁱⁱⁱ Statistical significance was calculated using the Fisher's exact probability test relative to P15 salineⁱⁱ and the corresponding DIV15 controlsⁱⁱⁱ. Statistical significance for SCR siRNA (scrambled siRNA) group is shown relative to the controlⁱⁱⁱ and Cx36 siRNA^{iv}.

^v P value cannot be calculated. Bic/PYTX+A/C, culture treated with bicuculline, picrotoxin, AP5, and CNQX. For drug concentrations, see the text.